Nuvation Bio (NUVB) Competitors

Viking Therapeutics (NASDAQ:VKTX) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings.

Which has more risk & volatility, VKTX or NUVB?

Viking Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Which has preferable earnings & valuation, VKTX or NUVB?

Nuvation Bio has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$109.96M	-$1.15	-23.91
Nuvation Bio	$10.96M	63.20	-$75.80M	-$2.35	-0.87

Do insiders and institutionals hold more shares of VKTX or NUVB?

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 4.1% of Viking Therapeutics shares are held by insiders. Comparatively, 29.9% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is VKTX or NUVB more profitable?

Viking Therapeutics' return on equity of -11.93% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-11.93%	-11.57%
Nuvation Bio	N/A	-21.89%	-17.86%

Do analysts recommend VKTX or NUVB?

Viking Therapeutics currently has a consensus target price of $87.15, indicating a potential upside of 216.98%. Nuvation Bio has a consensus target price of $7.83, indicating a potential upside of 284.93%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Viking Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nuvation Bio	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Does the media refer more to VKTX or NUVB?

In the previous week, Viking Therapeutics had 6 more articles in the media than Nuvation Bio. MarketBeat recorded 13 mentions for Viking Therapeutics and 7 mentions for Nuvation Bio. Viking Therapeutics' average media sentiment score of 1.37 beat Nuvation Bio's score of 1.03 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	11 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor VKTX or NUVB?

Viking Therapeutics received 578 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 81.43% of users gave Nuvation Bio an outperform vote while only 80.08% of users gave Viking Therapeutics an outperform vote.

Company	Underperform	Outperform
Viking Therapeutics	Outperform Votes 635 80.08%	Underperform Votes 158 19.92%
Nuvation Bio	Outperform Votes 57 81.43%	Underperform Votes 13 18.57%

Summary

Viking Therapeutics beats Nuvation Bio on 9 of the 17 factors compared between the two stocks.